Business Wire

Ipsen and Interprotein enter into a research collaboration for novel peptides in endocrinology

Del

Regulatory News:

Ipsen (Euronext: IPN, ADR: IPSEY), a global specialty driven pharmaceutical Group, and Interprotein Corporation (Interprotein), a Japanese R&D focused biotechnology company, today announced that they have signed a research collaboration and an option agreement to develop and commercialize new therapeutic peptides intended for serious medical conditions in endocrinology, such as Cushing’s disease.

Under the terms of the agreement, Ipsen will combine its expertise in design and development of therapeutic peptides targeting specific receptors with Interprotein’s Protein-Protein Interaction (PPI) and helix-loop-helix-peptide (HLHP) technologies.

“We are very excited to be involved in Ipsen’s innovative drug discovery program for this rare disease. We are particularly proud that our technological platform has been selected to advance Ipsen’s target molecules. This agreement fits our strategy to partner on PPI targeted Drug Discovery activities," said Masato Hosoda, Chief Executive Officer at Interprotein. “Our intention is for this partnership between Ipsen and Interprotein to potentially provide an innovative solution to improve quality of life of patients with serious diseases, and consequently reinforce the value of HLHP as therapeutic PPI inhibitors," said Hirotsugu Komatsu, Ph.D., Chief Scientific Officer at Interprotein.

Claude Bertrand, Executive Vice president R&D, Chief Scientific Officer at Ipsen stated: “Ipsen looks forward to benefiting from Interprotein’s innovative peptide discovery technologies to support Ipsen’s leading therapeutic peptide R&D capabilities and to developing new therapeutic solutions for serious unmet medical needs. Such a collaboration exemplifies Ipsen’s strategy in R&D where open innovation and partnerships are key to advance treatments in its focused medical areas.

Under the financial terms of the agreement, should Ipsen exercise its option and fully develop the compound(s), payments to Interprotein could reach up to €165 million, in upfront, success-driven R&D, regulatory and commercial milestones, with additional royalties on world-wide annual net sales.

About Interprotein

Interprotein is focusing on PPIs as drug targets with great potential and conducing drug discovery research of PPI antagonists and agonists using two technology platforms, i.e. helix-loop-helix peptides (HLHP) and INTerprotein’s Engine for New Drug Design (INTENDD®). HLHP is a conformationally-constrained peptide with two helices linked on both sides, and INTENDD® is a strategic approach for structure-based drug discovery (SBDD) of small molecules and can efficiently identify new drug-like scaffolds by Structure-Based Scaffold Generation (SGSG®) method. For additional information, please visit http://www.interprotein.com.

About Ipsen

Ipsen is a global specialty-driven biotechnological group with total sales exceeding €1.2 billion in 2014. Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in 30 countries. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and urology-oncology. Ipsen’s commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from prostate cancer, bladder cancer or neuroendocrine tumors. Ipsen also has a significant presence in primary care. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs (Les Ulis, France; Slough/Oxford, UK; Cambridge, US). In 2014, R&D expenditure totaled close to €187 million, representing about 15% of Group sales. The Group has more than 4,500 employees worldwide. Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com

Ipsen Forward Looking Statements

The forward-looking statements, objectives and targets contained herein are based on the Group’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words "believes," "anticipates" and "expects" and similar expressions are intended to identify forward-looking statements, including the Group’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. The Group must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favourable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Group's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Group’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to the Group’s activities and financial results. The Group cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Group’s partners could generate lower revenues than expected. Such situations could have a negative impact on the Group’s business, financial position or performance. The Group expressly disclaims any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers.

Contact information

For further information:
Ipsen
Media
Didier Véron
Senior Vice-President, Public Affairs and Communication
Tel.: +33 (0)1 58 33 51 16
Fax: +33 (0)1 58 33 50 58
E-mail: didier.veron@ipsen.com
or
Financial Community
Stéphane Durant des Aulnois
Vice-President, Investor Relations
Tel.: +33 (0)1 58 33 60 09
Fax: +33 (0)1 58 33 50 63
E-mail: stephane.durant.des.aulnois@ipsen.com
or
Brigitte Le Guennec
Corporate External Communication
Tel.: +33 (0)1 58 33 51 17
Fax: +33 (0)1 58 33 50 58
E-mail : brigitte.le.guennec@ipsen.com
or
Côme de La Tour du Pin
Investor Relations Manager
Tel.: +33 (0)1 58 33 53 31
Fax: +33 (0)1 58 33 50 63
E-mail: come.de.la.tour.du.pin@ipsen.com
or
Interprotein
Hirotsugu Komatsu, Ph.D.
CSO and Director, R&D and BD Division
TEL: +81-(0)42-770-9477
FAX: +81-(0)42-770-9477
E-mail: komatsu@interprotein.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Westinghouse Electric Company Signs Cooperation Agreement for Lead-Cooled Fast Reactor Development22.2.2018 13:00Pressemelding

Westinghouse Electric Company has signed a Cooperation Agreement for lead-cooled fast reactor (LFR) technology development with the Italian National Agency for New Technologies, Energy and Sustainable Economic Development (ENEA) and Ansaldo Nucleare. The agreement demonstrates each party’s commitment to collaborating toward the development of a next-generation nuclear plant based on LFR technology, which is both “walk-away” safe and economically competitive across global energy markets. “This agreement is an exciting step towards the development of a lead-cooled fast reactor for the marketplace,” said Ken Canavan, Westinghouse chief technology officer and vice president, Global Technology Office. “The LFR is game-changing technology for clean energy industries, and Westinghouse is pleased to be working with such experienced partners to bring this innovative concept to fruition.” Beyond baseload electricity generation, the high-temperature operation of the LFR will allow for a broad ran

Mavenir Teams with Dell EMC to Deliver Expanded Cloud-Native NFV Solutions22.2.2018 13:00Pressemelding

Mavenir, a leader in mobile network transformation, today announced its collaboration with Dell EMC OEM Solutions to deliver a broad range of solutions for service providers and enterprises covering 5G Cloud RAN, Packet Core, IoT, VoLTE, VoWiFi and RCS on Mavenir’s cloud-native Open Stack NFV and container CloudRange™ platform. Communications service providers are under intense pressure to simultaneously drive new revenue streams and aggressively reduce costs as OTTs gain market share in voice and messaging services. This expanded collaboration directly addresses these challenges, bringing together Mavenir’s extensive software stack for mobile network providers and Dell EMC solutions for infrastructure, cloud and IOT to create new offerings and best practices that enable the cost effective and rapid evolution of service provider and enterprise networks. Mavenir and Dell EMC OEM will pursue advanced engineering engagements in Cloud RAN, IOT and Enterprise Private LTE Solutions, includin

Equifax Integrates Entersekt’s Digital Security System22.2.2018 12:35Pressemelding

Entersekt, a leader in push-based authentication and mobile app security, today announced a technology partnership with global information solutions company Equifax Inc. (NYSE:EFX). Equifax has licensed Entersekt’s product Transakt to serve as an additional layer of security protecting the Equifax online and mobile services. Transakt empowers consumers to play an active role in safeguarding their digital identities and accounts. Whenever access to a digital identity or account is required, an authentication request is pushed to their phone or tablet in real time. They approve or block access by simply tapping Accept or Reject. It’s a highly intuitive, one-touch user experience engineered for a mobile-first world. Transakt’s ease of use belies its advanced set of security features. Covered by 56 patents in the United States and elsewhere, the digital-certificate–based technology uniquely identifies each registered mobile device; ensures its continued integrity as a factor of authenticat

ImmerVision to Showcase AI-Ready Vision Technology at MWC 201822.2.2018 12:00Pressemelding

ImmerVision, a technology company enabling intelligent vision in all the world’s devices, announced today that it is uniquely prepared to provide AI-ready, data-rich image processing to today’s most incisive device makers and manufacturers. Indeed, ImmerVision is already providing such hyper-intelligent image capture capabilities to some of the world’s top brands. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180222005513/en/ ImmerVision Enables AI-ready intelligent devices include Acer Holo360, Quanta Pi SOLO, and Tamaggo 360LiveCam (Graphic: Business Wire) Based in Montreal, Canada, ImmerVision develops wide-angle panomorph lenses and data-augmented imaging algorithms, enabling creative manufacturers to see more and smarter while creating professional and consumer devices. “In our quest to enable intelligent vision in every device, ImmerVision has taken a great leap forward,” says Alessandro Gasparini, Executive Vice Presi

Kite, a Gilead Company, and Sangamo Therapeutics Announce Collaboration to Develop Next-Generation Engineered Cell Therapies for the Treatment of Cancer22.2.2018 12:00Pressemelding

Kite, a Gilead Company (Nasdaq:GILD) and Sangamo Therapeutics, Inc. (Nasdaq:SGMO) today announced the companies have entered into a worldwide collaboration using Sangamo’s zinc finger nuclease (ZFN) technology platform for the development of next-generation ex vivo cell therapies in oncology. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180222005488/en/ Kite will use Sangamo’s ZFN technology to modify genes to develop next-generation cell therapies for autologous and allogeneic use in treating different cancers. Allogeneic cell therapies from healthy donor cells or from renewable stem cells would provide a potential treatment option that can be accessed directly within the oncology infusion center, thus reducing the time to infusion for patients. Under the terms of the agreement, Sangamo will receive an upfront payment of $150 million and is eligible to receive up to $3.01 billion in potential payments, aggregated across 10

CorFlow Presents Fundamental New Insights into the Coronary Microcirculation at ACC22.2.2018 09:10Pressemelding

CorFlow Therapeutics AG (www.corflow-therapeutics.ch) today announced that the company will present fundamental new insights into the coronary microcirculation during the annual meeting of the American College of Cardiology (ACC) in Orlando, FL, March 10-12, 2018. CorFlow has since its foundation in June 2016 worked to document that the Controlled Flow Infusion (CoFITM) technology is able to measure the coronary microvascular status and provide therapy to the compromised coronary microcirculation at the same time. Microvascular obstruction (MVO) affects more than half of the acute heart attack patients and is an independent predictor for complications including heart failure which constitutes a high cost burden for the world-wide health care system. To address this large unmet medical need in interventional cardiology, CorFlow has developed an in-vivo model which reproducibly creates MVO in an occlusion-reperfusion model with very low complication rates. Using this in-vivo model, the C